Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-05-17

FDA Approved: BUPRENORPHINE TRANSDERMAL SYSTEM — Original Application (Alvogen Inc.)

View source ↗

Summary

FDA approved an original ANDA for buprenorphine transdermal system (generic buprenorphine) for chronic pain management.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BUPRENORPHINE TRANSDERMAL SYSTEM (buprenorphine)

Snippet

ORIG AP for BUPRENORPHINE TRANSDERMAL SYSTEM (BUPRENORPHINE)